Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment
- PMID: 33710917
- PMCID: PMC9810136
- DOI: 10.1200/OP.20.00614
Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment
Abstract
Purpose: Ductal carcinoma in situ (DCIS), a nonobligate precursor of breast cancer, is often aggressively managed with multimodal therapy. However, there is limited research on patients' preferences for trade-offs among treatment-related outcomes such as breast appearance, side effects, and future cancer risk. We sought to investigate whether women consider treatment features aside from cancer risk when making treatment choices for ductal carcinoma in situ and if so, to what degree other features influence these decisions.
Methods: A discrete choice experiment was administered to participants in a comprehensive cancer screening mammography clinic. The experimental design was used to generate constructed health profiles resulting from different management strategies. Health profiles were defined by breast appearance, severity of infection within the first year, chronic pain, hot flashes, and risk of developing or dying from breast cancer within 10 years.
Results: One hundred ninety-four women without a personal history of breast cancer completed the choice task. Across 10 choice questions, 29% always selected the health profile with a lower risk of invasive breast cancer (ie, dominated on cancer risk), regardless of the effects of treatment. For nonrisk dominators, breast cancer risk remained the most important factor but was closely followed by chronic pain (24% [95% CI, 20 to 28]) and infection (22% [95% CI, 18 to 25]). Depending on treatment outcomes, the tolerable increase in breast cancer risk was as high as 3.4%.
Conclusion: Most women were willing to make some trade-offs between invasive cancer risk and treatment-related outcomes. Our findings highlight the importance of shared decision-making weighing risks and benefits between patient and provider management of low-risk disease.
Figures



Similar articles
-
The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.Breast Cancer Res. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4. Breast Cancer Res. 2017. PMID: 28274272 Free PMC article.
-
Ductal Carcinoma In Situ - Quo Vadis?Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S5-S6. Chirurgia (Bucur). 2021. PMID: 34967322 Review.
-
Diagnosis and management of ductal carcinoma in situ (DCIS).Evid Rep Technol Assess (Full Rep). 2009 Sep;(185):1-549. Evid Rep Technol Assess (Full Rep). 2009. PMID: 20629475 Free PMC article. Review.
-
The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?Breast Cancer Res Treat. 2019 Apr;174(2):525-535. doi: 10.1007/s10549-018-05095-7. Epub 2018 Dec 18. Breast Cancer Res Treat. 2019. PMID: 30564969
-
Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.J Natl Cancer Inst. 2008 Feb 20;100(4):243-51. doi: 10.1093/jnci/djn010. Epub 2008 Feb 12. J Natl Cancer Inst. 2008. PMID: 18270338
Cited by
-
Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists.Cancers (Basel). 2021 Aug 6;13(16):3962. doi: 10.3390/cancers13163962. Cancers (Basel). 2021. PMID: 34439126 Free PMC article.
-
Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast.Histopathology. 2023 Jan;82(1):106-118. doi: 10.1111/his.14804. Histopathology. 2023. PMID: 36482277 Free PMC article. Review.
-
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial.JAMA Oncol. 2025 Mar 1;11(3):300-309. doi: 10.1001/jamaoncol.2024.6556. JAMA Oncol. 2025. PMID: 39665588 Clinical Trial.
-
The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review.Pharmacoeconomics. 2025 Aug;43(8):879-936. doi: 10.1007/s40273-025-01495-y. Epub 2025 May 21. Pharmacoeconomics. 2025. PMID: 40397369 Free PMC article.
References
-
- Welch HG: Overdiagnosis and mammography screening. BMJ 339:b1425, 2009 - PubMed
-
- Erbas B, Provenzano E, Armes J, et al. : The natural history of ductal carcinoma in situ of the breast: A review. Breast Cancer Res Treat 97:135-144, 2006 - PubMed
-
- Sanders ME, Schuyler PA, Dupont WD, et al. : The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103:2481-2484, 2005 - PubMed
-
- Collins LC, Tamimi RM, Baer HJ, et al. : Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: Results from the Nurses' Health Study. Cancer 103:1778-1784, 2005 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical